BioNTech
€76.95
1411
-€2.05-2.59% Friday 18:55
Statistiques
Jour Haut
-
Journée basse
-
52W Haut
-
52W Bas
-
Volume
-
Volume moyen
-
Cap boursière
17.94B
Ratio C/B
158.4
Rendement de dividendes
-
Dividende
-
Dividendes
0%Rendement de dividendes
Taux de Croissance sur 10A
S. O.
Taux de Croissance sur 5A
S. O.
Taux de Croissance sur 3A
S. O.
Taux de Croissance sur 1A
S. O.
Bénéfices
6MayConfirmé
BPA prévu
-1.17
BPA réel
-1.42
Sont également suivis
Cette liste est basée sur les listes de surveillance des personnes sur Stock Events qui suivent 22UA.F. Il ne s'agit pas d'une recommandation d'investissement.
Concurrents
Cette liste est une analyse basée sur les événements récents du marché. Ce n'est pas une recommandation d'investissement.
Moderna
MRNA
Cap boursière45.34B
Pfizer
PFE
Cap boursière158.95B
Novavax
NVAX
Cap boursière1.67B
Johnson & Johnson
JNJ
Cap boursière352.53B
Astrazeneca
AZN
Cap boursière239.79B
Sanofi
SNY
Cap boursière125.78B
GSK
GSK
Cap boursière80.5B
Arcturus Therapeutics
ARCT
Cap boursière577.69M
Incyte
INCY
Cap boursière12.87B
À propos de nous
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac
Show more...
PDG
Dr. Ugur Sahin M.D.
Employés
6133
Pays
US
ISIN
US09075V1026
WKN
000A2PSR2